Surgical Science Sweden AB (STU:4P41)

Q3 2025 Surgical Science Sweden AB Earnings Call Transcript

Nov 13, 2025 / 10:00 AM GMT

Release Date Price: €6.75 (-11.60%)

Transcript

Key Points

Positve

Surgical Science Sweden AB (SUSRF) achieved an all-time high in total sales of SEK 264 million for Q3 2025, despite a negative currency impact.
The company experienced a 14% growth compared to the same quarter last year, and a 19% growth when adjusted for currency effects.
The educational products business unit stabilized and showed an 8% growth compared to the same quarter in 2024, with a 26% increase from the previous quarter.
Industry OEM sales increased by 20%, with development revenue up by 131% compared to the same quarter in 2024.
Surgical Science Sweden AB (SUSRF) secured a potentially largest single deal in its history within the medical device simulation segment, indicating strong future revenue potential.

Negative

The gross margin declined to 65% from 69% last year, affected by strong simulator sales relative to license revenue and currency effects.
Sales in the Americas grew by only 9%, which was below expectations due to extended sales cycles in a tougher budgetary climate for hospitals.
Sales in the US for comparable units decreased, with the market showing signs of activity but still disappointing for Q3.
The UK market faced sluggishness due to funding allocation issues from the National Health Service, negatively impacting sales.
Intelligent Ultrasound, acquired by Surgical Science Sweden AB (SUSRF), continued to be loss-making, contributing to an operating loss of SEK 11 million for the quarter.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SUSW.ST - Surgical Science Sweden AB
Q3 2025 Surgical Science Sweden AB Earnings Call
Nov 13, 2025 / 10:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to Surgical Science Q3 Report 2025 presentation. During the Q&A session, participants can ask questions by pressing pound 5 on their telephone keypad. During the Q&A, we kindly ask participants to limit yourselves to two questions at first. If you have additional questions, please queue up again by pressing 5. Now I will hand over to the speakers CEO Tom Engl and CFO Anna Ahlberg. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Welcome to this earnings call for surgical Science for Q3 2025. My name is Tom England, CEO, and with me today

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.